Ontology type: schema:ScholarlyArticle Open Access: True
2021-02-09
AUTHORSCécile Pautas, Emmanuel Raffoux, Juliette Lambert, Ollivier Legrand, Sylvain Chantepie, Lauris Gastaud, Jean-Pierre Marolleau, Xavier Thomas, Pascal Turlure, Rebecca J. Benner, Erik Vandendries, Karïn Gogat, Hervé Dombret, Sylvie Castaigne
ABSTRACTThe phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients who received hematopoietic stem cell transplantation (HSCT) as follow-up therapy in ALFA-0701. Patients aged 50–70 years were randomized to standard chemotherapy with or without GO (3 mg/m2 on days 1, 4, and 7 of induction and day 1 on each of two consolidation courses). Allogeneic HSCT was recommended for patients in first complete remission with matched (related or unrelated) donor, except those with core-binding factor AML or normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+ AML. Eighty-five patients (GO: n = 32; control: n = 53) received HSCT in first complete remission or after relapse/primary induction failure. Three patients (GO: n = 2; control: n = 1 [received GO as follow-up therapy]) developed VOD/SOS after HSCT or conditioning. Post-transplant survival, non-relapse mortality, and relapse were not different between arms. Results indicate fractionated-dose GO as part of induction and consolidation chemotherapy for AML does not induce excess post-transplant VOD/SOS or mortality and thus does not preclude the use of HSCT as consolidation treatment. More... »
PAGES1474-1477
http://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4
DOIhttp://dx.doi.org/10.1038/s41409-020-01207-4
DIMENSIONShttps://app.dimensions.ai/details/publication/pub.1135279963
PUBMEDhttps://www.ncbi.nlm.nih.gov/pubmed/33564120
JSON-LD is the canonical representation for SciGraph data.
TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT
[
{
"@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json",
"about": [
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Medical and Health Sciences",
"type": "DefinedTerm"
},
{
"id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1112",
"inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/",
"name": "Oncology and Carcinogenesis",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Adult",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Consolidation Chemotherapy",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Gemtuzumab",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hematopoietic Stem Cell Transplantation",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Hepatic Veno-Occlusive Disease",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Humans",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Leukemia, Myeloid, Acute",
"type": "DefinedTerm"
},
{
"inDefinedTermSet": "https://www.nlm.nih.gov/mesh/",
"name": "Nucleophosmin",
"type": "DefinedTerm"
}
],
"author": [
{
"affiliation": {
"alternateName": "Service d\u2019H\u00e9matologie et de th\u00e9rapie cellulaire, H\u00f4pital Henri Mondor, Cr\u00e9teil, France",
"id": "http://www.grid.ac/institutes/grid.412116.1",
"name": [
"Service d\u2019H\u00e9matologie et de th\u00e9rapie cellulaire, H\u00f4pital Henri Mondor, Cr\u00e9teil, France"
],
"type": "Organization"
},
"familyName": "Pautas",
"givenName": "C\u00e9cile",
"id": "sg:person.01324451673.29",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01324451673.29"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France"
],
"type": "Organization"
},
"familyName": "Raffoux",
"givenName": "Emmanuel",
"id": "sg:person.01241622025.01",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01241622025.01"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France",
"id": "http://www.grid.ac/institutes/grid.418080.5",
"name": [
"Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Le Chesnay, France"
],
"type": "Organization"
},
"familyName": "Lambert",
"givenName": "Juliette",
"id": "sg:person.01365675644.91",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01365675644.91"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service d\u2019h\u00e9matologie clinique et de th\u00e9rapie cellulaire, H\u00f4pital Saint-Antoine (AP-HP), Universit\u00e9 Paris Pierre et Marie Curie, Paris, France",
"id": "http://www.grid.ac/institutes/grid.412370.3",
"name": [
"Service d\u2019h\u00e9matologie clinique et de th\u00e9rapie cellulaire, H\u00f4pital Saint-Antoine (AP-HP), Universit\u00e9 Paris Pierre et Marie Curie, Paris, France"
],
"type": "Organization"
},
"familyName": "Legrand",
"givenName": "Ollivier",
"id": "sg:person.0752753564.08",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752753564.08"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Institut d\u2019H\u00e9matologie de Basse-Normandie, Caen, France",
"id": "http://www.grid.ac/institutes/grid.411149.8",
"name": [
"Institut d\u2019H\u00e9matologie de Basse-Normandie, Caen, France"
],
"type": "Organization"
},
"familyName": "Chantepie",
"givenName": "Sylvain",
"id": "sg:person.0716120654.23",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716120654.23"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service h\u00e9matologie, Centre Lacassagne, Nice, France",
"id": "http://www.grid.ac/institutes/grid.417812.9",
"name": [
"Service h\u00e9matologie, Centre Lacassagne, Nice, France"
],
"type": "Organization"
},
"familyName": "Gastaud",
"givenName": "Lauris",
"id": "sg:person.01210567432.88",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01210567432.88"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service h\u00e9matologie, CHU Amiens, Amiens, France",
"id": "http://www.grid.ac/institutes/grid.134996.0",
"name": [
"Service h\u00e9matologie, CHU Amiens, Amiens, France"
],
"type": "Organization"
},
"familyName": "Marolleau",
"givenName": "Jean-Pierre",
"id": "sg:person.01226630333.19",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01226630333.19"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service h\u00e9matologie, Centre Hospitalier Lyon Sud, Lyon, France",
"id": "http://www.grid.ac/institutes/grid.411430.3",
"name": [
"Service h\u00e9matologie, Centre Hospitalier Lyon Sud, Lyon, France"
],
"type": "Organization"
},
"familyName": "Thomas",
"givenName": "Xavier",
"id": "sg:person.01271000165.93",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01271000165.93"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service h\u00e9matologie et de th\u00e9rapie cellulaire, CHU de Limoges, Limoges, France",
"id": "http://www.grid.ac/institutes/grid.411178.a",
"name": [
"Service h\u00e9matologie et de th\u00e9rapie cellulaire, CHU de Limoges, Limoges, France"
],
"type": "Organization"
},
"familyName": "Turlure",
"givenName": "Pascal",
"id": "sg:person.01050653075.03",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01050653075.03"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Global Product Development, Pfizer Inc, Groton, CT, USA",
"id": "http://www.grid.ac/institutes/grid.410513.2",
"name": [
"Global Product Development, Pfizer Inc, Groton, CT, USA"
],
"type": "Organization"
},
"familyName": "Benner",
"givenName": "Rebecca J.",
"id": "sg:person.01315444703.64",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01315444703.64"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Pfizer Inc, Cambridge, MA, USA",
"id": "http://www.grid.ac/institutes/grid.410513.2",
"name": [
"Pfizer Inc, Cambridge, MA, USA"
],
"type": "Organization"
},
"familyName": "Vandendries",
"givenName": "Erik",
"id": "sg:person.01256437330.14",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01256437330.14"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Global Clinical Development, Pfizer Inc, Paris, France",
"id": "http://www.grid.ac/institutes/grid.476471.7",
"name": [
"Global Clinical Development, Pfizer Inc, Paris, France"
],
"type": "Organization"
},
"familyName": "Gogat",
"givenName": "Kar\u00efn",
"id": "sg:person.01255312226.68",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01255312226.68"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France",
"id": "http://www.grid.ac/institutes/grid.413328.f",
"name": [
"H\u00f4pital Saint-Louis (AP-HP), EA 3518, Universit\u00e9 de Paris, Paris, France"
],
"type": "Organization"
},
"familyName": "Dombret",
"givenName": "Herv\u00e9",
"id": "sg:person.01036301740.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01036301740.76"
],
"type": "Person"
},
{
"affiliation": {
"alternateName": "Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Universit\u00e9 de Versailles Saint Quentin, Le Chesnay, France",
"id": "http://www.grid.ac/institutes/grid.418080.5",
"name": [
"Service d\u2019H\u00e9matologie et Oncologie, Centre Hospitalier de Versailles, Universit\u00e9 de Versailles Saint Quentin, Le Chesnay, France"
],
"type": "Organization"
},
"familyName": "Castaigne",
"givenName": "Sylvie",
"id": "sg:person.0770166540.76",
"sameAs": [
"https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0770166540.76"
],
"type": "Person"
}
],
"citation": [
{
"id": "sg:pub.10.1038/bmt.2016.302",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1023654702",
"https://doi.org/10.1038/bmt.2016.302"
],
"type": "CreativeWork"
},
{
"id": "sg:pub.10.1007/s00277-016-2899-0",
"sameAs": [
"https://app.dimensions.ai/details/publication/pub.1015754901",
"https://doi.org/10.1007/s00277-016-2899-0"
],
"type": "CreativeWork"
}
],
"datePublished": "2021-02-09",
"datePublishedReg": "2021-02-09",
"description": "The phase 3 ALFA-0701 trial demonstrated improved outcomes with fractionated-dose gemtuzumab ozogamicin (GO) combined with standard chemotherapy vs. standard chemotherapy alone in adults with de novo acute myeloid leukemia (AML). We examined post-transplant outcomes and occurrence of hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS) in patients who received hematopoietic stem cell transplantation (HSCT) as follow-up therapy in ALFA-0701. Patients aged 50\u201370 years were randomized to standard chemotherapy with or without GO (3\u2009mg/m2 on days 1, 4, and 7 of induction and day 1 on each of two consolidation courses). Allogeneic HSCT was recommended for patients in first complete remission with matched (related or unrelated) donor, except those with core-binding factor AML or normal karyotype and either NPM1+/FLT3-ITDwt or CEBPA+ AML. Eighty-five patients (GO: n\u2009=\u200932; control: n\u2009=\u200953) received HSCT in first complete remission or after relapse/primary induction failure. Three patients (GO: n\u2009=\u20092; control: n\u2009=\u20091 [received GO as follow-up therapy]) developed VOD/SOS after HSCT or conditioning. Post-transplant survival, non-relapse mortality, and relapse were not different between arms. Results indicate fractionated-dose GO as part of induction and consolidation chemotherapy for AML does not induce excess post-transplant VOD/SOS or mortality and thus does not preclude the use of HSCT as consolidation treatment.",
"genre": "article",
"id": "sg:pub.10.1038/s41409-020-01207-4",
"inLanguage": "en",
"isAccessibleForFree": true,
"isPartOf": [
{
"id": "sg:journal.1096890",
"issn": [
"0268-3369",
"1476-5365"
],
"name": "Bone Marrow Transplantation",
"publisher": "Springer Nature",
"type": "Periodical"
},
{
"issueNumber": "6",
"type": "PublicationIssue"
},
{
"type": "PublicationVolume",
"volumeNumber": "56"
}
],
"keywords": [
"hematopoietic stem cell transplantation",
"acute myeloid leukemia",
"VOD/SOS",
"first complete remission",
"gemtuzumab ozogamicin",
"stem cell transplantation",
"standard chemotherapy",
"complete remission",
"cell transplantation",
"myeloid leukemia",
"hepatic veno-occlusive disease/sinusoidal obstruction syndrome",
"veno-occlusive disease/sinusoidal obstruction syndrome",
"allogeneic hematopoietic stem cell transplantation",
"de novo acute myeloid leukemia",
"use of HSCT",
"novo acute myeloid leukemia",
"core-binding factor acute myeloid leukemia",
"factor acute myeloid leukemia",
"primary induction failure",
"non-relapse mortality",
"post-transplant outcomes",
"sinusoidal obstruction syndrome",
"post-transplant survival",
"part of induction",
"consolidation chemotherapy",
"obstruction syndrome",
"induction failure",
"improved outcomes",
"chemotherapy",
"patients",
"consolidation treatment",
"normal karyotype",
"ozogamicin",
"remission",
"transplantation",
"alfa",
"outcomes",
"leukemia",
"mortality",
"relapse",
"syndrome",
"therapy",
"trials",
"survival",
"adults",
"treatment",
"induction",
"failure",
"arm",
"years",
"karyotype",
"donors",
"occurrence",
"SOS",
"conditioning",
"use",
"results",
"part"
],
"name": "Outcomes following hematopoietic stem cell transplantation in patients treated with standard chemotherapy with or without gemtuzumab ozogamicin for acute myeloid leukemia",
"pagination": "1474-1477",
"productId": [
{
"name": "dimensions_id",
"type": "PropertyValue",
"value": [
"pub.1135279963"
]
},
{
"name": "doi",
"type": "PropertyValue",
"value": [
"10.1038/s41409-020-01207-4"
]
},
{
"name": "pubmed_id",
"type": "PropertyValue",
"value": [
"33564120"
]
}
],
"sameAs": [
"https://doi.org/10.1038/s41409-020-01207-4",
"https://app.dimensions.ai/details/publication/pub.1135279963"
],
"sdDataset": "articles",
"sdDatePublished": "2022-06-01T22:22",
"sdLicense": "https://scigraph.springernature.com/explorer/license/",
"sdPublisher": {
"name": "Springer Nature - SN SciGraph project",
"type": "Organization"
},
"sdSource": "s3://com-springernature-scigraph/baseset/20220601/entities/gbq_results/article/article_891.jsonl",
"type": "ScholarlyArticle",
"url": "https://doi.org/10.1038/s41409-020-01207-4"
}
]Download the RDF metadata as: json-ld nt turtle xml License info
JSON-LD is a popular format for linked data which is fully compatible with JSON.
curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'
N-Triples is a line-based linked data format ideal for batch operations.
curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'
Turtle is a human-readable linked data format.
curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'
RDF/XML is a standard XML format for linked data.
curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1038/s41409-020-01207-4'
This table displays all metadata directly associated to this object as RDF triples.
285 TRIPLES
22 PREDICATES
94 URIs
84 LITERALS
15 BLANK NODES